Skip to main content
Contact Us
Subscribe
E-Edition
55°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Vyne Therapeutics Inc
(NQ:
VYNE
)
2.670
+0.020 (+0.75%)
Streaming Delayed Price
Updated: 3:59 PM EDT, May 10, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Vyne Therapeutics Inc
< Previous
1
2
3
4
5
Next >
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
March 23, 2023
We're starting off the day with a look at the biggest pre-market stock movers traders need to know about on Thursday morning!
Via
InvestorPlace
12 Health Care Stocks Moving In Wednesday's After-Market Session
February 08, 2023
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
January 13, 2023
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
January 11, 2023
Via
Benzinga
Why Penny Stock VYNE Therapeutics Is Skyrocketing Today?
January 10, 2023
Via
Benzinga
VYNE Therapeutics: Q2 Earnings Insights
August 12, 2022
VYNE Therapeutics (NASDAQ:VYNE) reported its Q2 earnings results on Friday, August 12, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Dow Rises Over 100 Points; Rayonier Advanced Materials Shares Plunge
January 10, 2023
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining more than 100 points on Tuesday. The Dow traded up 0.40% to 33,653.27 while the NASDAQ rose 0.83% to 10,724.37. The S&P...
Via
Benzinga
Why Bed Bath & Beyond Shares Are Trading Higher By 17%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
January 10, 2023
Gainers
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
January 10, 2023
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
January 10, 2023
Via
Benzinga
Why VYNE Therapeutics Shares Are Trading Higher By 82%; Here Are 20 Stocks Moving Premarket
January 10, 2023
Gainers VYNE Therapeutics Inc. (NASDAQ: VYNE) rose 82.2% to $0.35 in pre-market trading after the company said first vitiligo patient was dosed in Phase 1a/b clinical trial of novel BET inhibitor...
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
January 10, 2023
We're starting off the day with an overview of the biggest pre-market stock movers traders need to know about for Tuesday!
Via
InvestorPlace
12 Health Care Stocks Moving In Monday's After-Market Session
January 09, 2023
Via
Benzinga
Why Cutera Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Monday's Mid-Day Session
January 09, 2023
Gainers CinCor Pharma, Inc. (NASDAQ: CINC) shares jumped 137% to $27.93 after AstraZeneca announced it will acquire the company for $26 per share in cash.
Via
Benzinga
Why CinCor Pharma Shares Are Trading Higher By 140%; Here Are 20 Stocks Moving Premarket
January 09, 2023
Gainers CinCor Pharma, Inc. (NASDAQ: CINC) rose 140.2% to $28.30 in pre-market trading after AstraZeneca announced plans to buy the company for up to $1.8 billion.
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
January 09, 2023
We're starting off the week with a look at the biggest pre-market stock movers traders need to know about on Monday morning!
Via
InvestorPlace
12 Health Care Stocks Moving In Friday's After-Market Session
January 06, 2023
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
January 05, 2023
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
January 04, 2023
Via
Benzinga
Why ABVC BioPharma Shares Are Trading Higher By 129%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
January 05, 2023
Gainers Bellerophon Therapeutics, Inc. (NASDAQ: BLPH) shares surged 179.3% to $2.4585 after the company announced that it has entered into a license agreement for the development and commercialization...
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
January 04, 2023
Via
Benzinga
Stocks That Hit 52-Week Lows On Thursday
September 22, 2022
On Thursday, 1076 companies hit new 52-week lows.
Via
Benzinga
VYNE Therapeutics Earnings Perspective: Return On Capital Employed
September 09, 2022
VYNE Therapeutics (NASDAQ:VYNE) brought in sales totaling $126 thousand during Q2 according to data provided by Benzinga Pro. However, earnings decreased 281.5%, resulting in a loss of $8.48 million.
Via
Benzinga
Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary
August 10, 2022
Via
Benzinga
Why Invitae Climbed Around 279%; Here Are 98 Biggest Movers From Yesterday
August 11, 2022
Gainers Invitae Corporation (NYSE: NVTA) surged 278.5% to close at $8.63 after the company reported better-than-expected Q2 EPS.
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
August 10, 2022
Via
Benzinga
Biotech Daily: Cancer Causing Impurities In Merck's Diabetic Drug, Vir Bio-GSK Shun FDA Submission Plans For COVID-19 Treatment, Aethlon's Monkeypox Trial
August 10, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
VYNE Therapeutics Shares Plummet As Mid-Stage Skin Disease Study Missed Primary Endpoint
August 10, 2022
VYNE Therapeutics Inc. (NASDAQ: VYNE) announced results from the Phase 2a segment of a Phase 1b/2a clinical trial evaluating FMX114 for the treatment of mild-to-moderate atopic dermatitis (AD).
Via
Benzinga
VYNE Therapeutics Shares Disappointing Data From Atopic Dermatitis Trial
August 10, 2022
VYNE Therapeutics Inc (NASDAQ: VYNE) has announced results from the Phase 2a segment of Phase 1b/2a trial evaluating FMX114 for mild-to-moderate atopic dermatitis.
Via
Benzinga
VYNE Therapeutics Concludes Patient Enrolment in Mid-Stage Study Of Skin Inflammation Candidate
June 17, 2022
VYNE Therapeutics Inc. (NASDAQ: VYNE) has concluded patient enrollment in the Phase 2a study of of its drug candidate FMX114 for the treatment of mild-to-moderate atopic dermatitis (AD).
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.